Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: Triffin who wrote (822)	9/24/1998 5:22:00 PM
From: Candle stick	Respond to of 947

Hi James, nice to see a new face on this board. Looks like my excursion into other forums is paying off. Why is Gary Gelman consistently selling out even at these prices???? It is my understanding that Gelman received a sweetheart deal from MSON. He held approx. 1.5 million shares and options. I believe he currently has less than 100,000 shares of stock left and about 650,000 options(numbers are approx. I could be a little off). He really has nothing to do with this company even though he is CEO. He did not do what the company expected from him, namely create visibility. He has been selling his stock for almost a year now at every price under the sun from 5-15 dollars....He received almost all of it, and options, at about 1 dollar...It is my understanding that he simply wanted to diversify his holdings since he struck it big. I believe he is selling all his stock and will keep his options, since there is less risk in the options. He is the supply in the stock. I believe he is nearly done selling the stock, or perhaps finished altogether now. What is the bottom line impact to MSON assuming they lose the upcoming patent infringement suit with MNTR??? Would this be a company killer??? In my opinion, NOT AT ALL. If they actually lost the case, the other businesses would still give the company a value somewhere in this neighborhood, IMHO....remember, they still have the core scrubber businesses and US Surgical ultrasonic scalpel deal, plus 3 new products currently in development. Needless to say I believe that MSON will win the case. Period. Mentor brought the suit to try disrupt business so that they could catch up with their own inferior product. I have spoken with surgeons that have used both products and they prefer MSON product. I have spoken with 2 patent attorneys, and they believe there is NO patent infringement. They believe the case to be frivolous. One of the recent buyers has been a patent attorney. This is a tiny company. 5.7 million shares outstanding and 2 million held by insiders...at 6 dollars it is valued at less than 35 million dollars...that is why noone is looking at it. MSON has applied for full Nasdaq listing(currently small cap) and expect to get it soon...IMHO you are looking at maybe 1 dollar downside an 10 dollars upside...to me that is a great value play. Please note that there is a very active discussion on MSON on the Yahoo! message boards messages.yahoo.com , and there are 2 people there, Wesley0428 and ghost5995 that are extremely knowledgeable about MSON, and the lawsuit....they can give you much more info than I can. Hope to see you there.......;^)

To: Triffin who wrote (822)	9/24/1998 5:27:00 PM
From: Candle stick	Respond to of 947

James, from the 10K, filed yesterday: From form 10K filed today, Sept. 23: Item 3. Legal Proceedings. The Company, Medical Device Alliance, Inc. ("MDA"), and MDA's wholly-owned subsidiary, Lysonix, Inc., are defendants in an action alleging patent infringement filed by Mentor. Both the Company and its licensee (MDA) are aggressively contesting Mentor's claim. A motion for preliminary injunction filed by Mentor, requesting that the Company and its licensees be precluded from selling the ultrasonic soft tissue aspirator, was heard and dismissed by the U.S. District Court on September 11, 1998, at which time a trial on the merits was scheduled for January 1999. Based upon the current status of matters, management believes that the outcome of this suit will not have a material adverse effect on the Company's consolidated financial position and consolidated results of operations.